The theory that fetal blood possesses a high immunobiologic antiblastic quality against neoplasms caused Bruskin and Farberova1 of the Oncologic Institute of Moscow to attempt the use of placental blood for massive transfusions during surgical treatment of malignant neoplasms. The blood was obtained from the umbilical vein and the placenta of the new-born. The amount obtainable from one placenta varied between 50 and 120 cc. It was found that the hemoglobin of the placental blood varied from 90 to 120 per cent (the method of determination not stated), erythrocytes from 5,000,000 to 6,000,000, and leukocytes from 8,000 to 16,000, with a definite lymphocytosis (from 32 to 46 per cent). The reticulocytes varied from 11 to 30 in 1,000 cells. The observers believe that placental blood contains a number of hormones of ovarian and anterior pituitary origin. The blood was conserved for from six to ten days. Bruskin and Farberova estimate
A NEW SOURCE OF BLOOD FOR TRANSFUSION. JAMA. 1938;110(14):1113–1114. doi:10.1001/jama.1938.02790140045013
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: